Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H30NO3.Br |
Molecular Weight | 448.393 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].CC(C)[N+](C)(CCOC(=O)C1C2=C(OC3=C1C=CC=C3)C=CC=C2)C(C)C
InChI
InChIKey=XLBIBBZXLMYSFF-UHFFFAOYSA-M
InChI=1S/C23H30NO3.BrH/c1-16(2)24(5,17(3)4)14-15-26-23(25)22-18-10-6-8-12-20(18)27-21-13-9-7-11-19(21)22;/h6-13,16-17,22H,14-15H2,1-5H3;1H/q+1;/p-1
DescriptionSources: https://www.drugs.com/pro/propantheline.htmlCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00782 | http://reference.medscape.com/drug/pro-banthine-propantheline-342000 | https://www.ncbi.nlm.nih.gov/pubmed/12049493
Sources: https://www.drugs.com/pro/propantheline.html
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00782 | http://reference.medscape.com/drug/pro-banthine-propantheline-342000 | https://www.ncbi.nlm.nih.gov/pubmed/12049493
Propantheline is an antimuscarinic agent used for the treatment of excessive sweating (hyperhidrosis), cramps or spasms of the stomach, intestines (gut) or bladder, and involuntary urination (enuresis). It can also be used to control the symptoms of irritable bowel syndrome and similar conditions. Propantheline is one of a group of antispasmodic medications which work by blocking the action of the chemical messenger acetylcholine, which is produced by nerve cells, to muscarinic receptors present in various smooth muscular tissues, in places such as the gut, bladder, and eye. Normally, the binding of acetylcholine induces involuntary smooth muscular contractions. Varying degrees of drying of salivary secretions may occur as well as decreased sweating. Ophthalmic side effects include blurred vision, mydriasis, cycloplegia, and increased ocular tension. Other reported adverse reactions include urinary hesitancy and retention, tachycardia, palpitations, loss of the sense of taste, headache, nervousness, mental confusion, drowsiness, weakness, dizziness, insomnia, nausea, vomiting, constipation, bloated feeling, impotence, suppression of lactation, and allergic reactions or drug idiosyncrasies including anaphylaxis, urticaria and other dermal manifestations.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12049493 |
9.48 null [pKi] | ||
Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12049493 |
9.66 null [pKi] | ||
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12049493 |
10.04 null [pKi] | ||
Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12049493 |
10.24 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PRO-BANTHINE Approved UsePropantheline bromide is effective as adjunctive therapy in the treatment of peptic ulcer. Launch Date1953 |
|||
Primary | PRO-BANTHINE Approved UsePropantheline bromide is effective as adjunctive therapy in the treatment of peptic ulcer. Launch Date1953 |
|||
Primary | PRO-BANTHINE Approved UsePropantheline bromide is effective as adjunctive therapy in the treatment of peptic ulcer. Launch Date1953 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
51.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6689152 |
45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
53.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389749 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
20.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389749 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
186.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6689152 |
45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
159 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389749 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
62.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389749 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389749 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.57 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389749 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Sick sinus syndrome in nine West Highland white terriers. | 2001 Feb 3 |
|
[Protein-losing syndrome of the gastrointestinal tract]. | 2001 Oct 26 |
|
Taurine in submandibular gland of the rat: effect of muscarinic drugs. | 2002 Apr |
|
Influence of prokinetics on the gastrointestinal transit and residence times of activated charcoal. | 2002 Aug |
|
Clinical pharmacokinetics of drugs used to treat urge incontinence. | 2003 |
|
Interventions for preventing oral mucositis for patients with cancer receiving treatment. | 2003 |
|
Variable effects of previously untested muscarinic receptor antagonists on experimental myopia. | 2003 Mar |
|
Propantheline and in vitro reactivity of urinary bladder smooth muscle in guinea pigs. | 2005 |
|
Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. | 2005 Jun |
|
Masking mechanisms of bitter taste of drugs studied with ion selective electrodes. | 2006 Aug |
|
Clomipramine-induced mood and perceived performance changes in selected healthy individuals. | 2007 Jun |
|
Interventions for preventing oral mucositis for patients with cancer receiving treatment. | 2007 Oct 17 |
|
The effectiveness of intravesical oxybutynin, propantheline, and capsaicin in the management of neuropathic bladder following spinal cord injury. | 2007 Oct 22 |
|
Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin. | 2008 |
|
No effect of imidafenacin, a novel antimuscarinic drug, on digoxin pharmacokinetics in healthy subjects. | 2008 |
|
Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. | 2008 Apr |
|
Methyl 9H-xanthene-9-carboxyl-ate. | 2008 Apr 16 |
|
Pharmacological interventions for clozapine-induced hypersalivation. | 2008 Jul |
|
Pharmacological interventions for clozapine-induced hypersalivation. | 2008 Jul 16 |
|
Using the zebrafish lateral line to screen for ototoxicity. | 2008 Jun |
|
Cycloheximide and disulfoton are positive in the photoclastogencity assay but do not absorb UV irradiation: another example of pseudophotoclastogenicity? | 2008 Mar |
|
Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations. | 2008 Nov |
|
Locked-in Syndrome in a Nigerian male with Multiple Sclerosis: a case report and literature review. | 2008 Oct 30 |
|
Response to "Suspected differential interactions of digoxin with imidafenacin and propantheline; some thoughts for introspection". | 2009 |
|
Desirable pharmacokinetic properties of (13)C-uracil as a breath test probe of gastric emptying in comparison with (13)C-acetate and (13)C-octanoate in rats. | 2009 |
|
Suspected differential interactions of digoxin with imidafenacin and propantheline; some thoughts for introspection. | 2009 |
|
Anticholinergics for urinary symptoms in multiple sclerosis. | 2009 Jan 21 |
|
A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. | 2009 Jul 22 |
|
Oxybutynin extended release for the management of overactive bladder: a clinical review. | 2009 Sep 21 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
New approaches in the management of multiple sclerosis. | 2010 Nov 24 |
|
New insights into molecular targets for urinary incontinence. | 2010 Oct |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/propantheline.html
The usual initial adult dose of Propantheline bromide tablets is 15 mg taken 30 minutes before each meal and 30 mg at bedtime (a total of 75 mg daily). Subsequent dosage adjustment should be made according to the patient’s individual response and tolerance.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12049493
Binding studies were performed with [3 H]NMS following the protocol from RBI. The binding buffer, pH 7.4, consisted of 0.15 M NaCl, 1.5 mM KH2 PO4 , and 2.7 mM Na2 HPO4 . NaF 10 mM was added to the buffer as an esterase inhibitor. The assay mixture (1 mL) contained 100 μL diluted membranes (receptor proteins, final concentration: m1 25 μg/mL, m2 42 μg/mL, m3 15.9 μg/mL, m4 20 μg/mL). Final concentrations of [3 H]NMS for the m2-m4 binding studies were 0.5 nM and 1 nM for m1. Specific binding was defined as the difference between the [3 H]NMS binding in the absence and presence of 1 μM atropine. Incubation was carried out at room temperature for 60 minutes. The assay was terminated by filtration through a Whatman GF/B filter (presoaked with 0.5% polyethyleneimine). The filter was then washed 3 times with 10 mL ice-cold binding buffer, transferred to vials, and added with 10 mL of Scintiverse liquid. Finally, detection was performed on a Packard 31800 liquid scintillation analyzer
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C29383
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
100000081151
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
SUB10098MIG
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
UX9Z118X9F
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
m9189
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
UX9Z118X9F
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
226
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
8762
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1180725
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
757294
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
9279
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
200-030-6
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
DBSALT000225
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
DTXSID2023519
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
1570508
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
PROPANTHELINE BROMIDE
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
50-34-0
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD